secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001104659-23-125170
Event type: litigation
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia faces new PH-ILD patent infringement suit from United Therapeutics on '327 Patent
--------------------------------------------------------------------------------

- United Therapeutics filed amended complaint Nov 30, 2023, alleging YUTREPIA infringes new '327 Patent covering inhaled treprostinil for PH-ILD.
- The '327 Patent issued Nov 28, 2023; Liquidia argues no 30-month stay because it issued after original NDA filing.
- Ongoing IPR of '793 Patent: PTAB ruled claims unpatentable; appeal pending at Federal Circuit after Dec 4, 2023 oral argument.
- Liquidia intends to vigorously defend; previous Hatch-Waxman ruling still blocks YUTREPIA approval for PH-ILD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923125170/0001104659-23-125170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923125170/tm2332679d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-125170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer